Innate Pharma Toekomstige groei

Future criteriumcontroles 2/6

Innate Pharma zal naar verwachting groeien in winst en omzet met respectievelijk 36.6% en 26.2% per jaar. De winst per aandeel zal naar verwachting groeien met 106.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -132.3% zijn.

Belangrijke informatie

36.6%

Groei van de winst

106.2%

Groei van de winst per aandeel

Biotechs winstgroei	4.6%
Inkomstengroei	26.2%
Toekomstig rendement op eigen vermogen	-132.3%
Dekking van analisten	Good
Laatst bijgewerkt	19 Nov 2024

Recente toekomstige groei-updates

Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year

Mar 24

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Innate Pharma S.A. (EPA:IPH)

Oct 24

Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price

May 21

Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year

Mar 24

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Dec 21

Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher

Sep 30

Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates

Sep 16

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Jun 09

News Flash: Analysts Just Made A Massive Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts

Mar 30

Rainbows and Unicorns: Innate Pharma S.A. (EPA:IPH) Analysts Just Became A Lot More Optimistic

Dec 18

Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?

Sep 27

Innate Pharma S.A. (EPA:IPH) Analysts Are Reducing Their Forecasts For This Year

Aug 04

Industry Analysts Just Made A Dazzling Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

May 12

Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Apr 13

Time To Worry? Analysts Just Downgraded Their Innate Pharma S.A. (EPA:IPH) Outlook

Mar 26

Is Innate Pharma (EPA:IPH) Weighed On By Its Debt Load?

Nov 11

Winst- en omzetgroeiprognoses

ENXTPA:IPH - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	103	-14	69	174	5
12/31/2025	86	10	34	99	6
12/31/2024	54	-22	28	38	6
6/30/2024	34	-34	-20	-18	N/A
3/31/2024	48	-21	-28	-25	N/A
12/31/2023	62	-8	-35	-33	N/A
9/30/2023	57	-35	-34	-32	N/A
6/30/2023	52	-63	-33	-32	N/A
3/31/2023	55	-60	-27	-25	N/A
12/31/2022	58	-58	-20	-19	N/A
9/30/2022	57	-40	-24	-23	N/A
6/30/2022	57	-22	-28	-26	N/A
3/31/2022	41	-34	-44	-42	N/A
12/31/2021	25	-45	-60	-58	N/A
6/30/2021	46	-8	-27	-25	N/A
3/31/2021	58	-4	-45	-38	N/A
12/31/2020	70	-1	-63	-52	N/A
9/30/2020	67	-54	-78	-67	N/A
6/30/2020	63	-44	-93	-83	N/A
3/31/2020	75	-33	-62	-24	N/A
12/31/2019	85	8	-30	35	N/A
9/30/2019	108	5	-17	48	N/A
6/30/2019	130	31	-4	61	N/A
3/31/2019	112	17	-19	14	N/A
12/31/2018	94	3	-34	-33	N/A
9/30/2018	70	-19	-49	-46	N/A
6/30/2018	46	-40	-64	-59	N/A
3/31/2018	45	-44	N/A	-53	N/A
12/31/2017	44	-48	N/A	-48	N/A
9/30/2017	55	-28	N/A	-43	N/A
6/30/2017	66	-8	N/A	-38	N/A
3/31/2017	66	3	N/A	-37	N/A
12/31/2016	66	13	N/A	-37	N/A
9/30/2016	53	5	N/A	-33	N/A
6/30/2016	41	-2	N/A	-29	N/A
3/31/2016	33	-4	N/A	86	N/A
12/31/2015	25	-7	N/A	202	N/A
9/30/2015	17	-13	N/A	200	N/A
6/30/2015	8	-19	N/A	199	N/A
3/31/2015	8	-19	N/A	91	N/A
12/31/2014	8	-20	N/A	-18	N/A
9/30/2014	11	-15	N/A	-15	N/A
6/30/2014	14	-10	N/A	-12	N/A
3/31/2014	15	-6	N/A	-11	N/A
12/31/2013	17	-3	N/A	-11	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat IPH de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat IPH de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat IPH de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van IPH ( 26.2% per jaar) zal naar verwachting sneller groeien dan de markt French ( 5.6% per jaar).

Hoge groei-inkomsten: De omzet van IPH ( 26.2% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat IPH binnen 3 jaar verliesgevend zal zijn.

Innate Pharma Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 275%, revenue upgraded

No longer forecast to breakeven

Consensus estimates of losses per share improve by 14%

Consensus EPS estimates increase from loss to €0.21 profit

Forecast to breakeven in 2026

Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year

Recent updates

Innate Pharma S.A., Annual General Meeting, May 22, 2025

Innate Pharma S.A. to Report First Half, 2025 Results on Sep 17, 2025

Risks To Shareholder Returns Are Elevated At These Prices For Innate Pharma S.A. (EPA:IPH)

Innate Pharma SA Announces Board Changes

Araris Biotech AG entered into an agreement to acquire ADC Transglutaminase Conjugation Technology Patents Portfolio from Innate Pharma S.A. (ENXTPA:IPH).

Consensus EPS estimates fall by 275%, revenue upgraded

First half 2024 earnings: EPS in line with analyst expectations despite revenue beat

New minor risk - Profitability

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

New minor risk - Profitability

No longer forecast to breakeven

Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides

Consensus estimates of losses per share improve by 14%

Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Consensus EPS estimates increase from loss to €0.21 profit

Forecast to breakeven in 2026

Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

New minor risk - Share price stability

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher

Consensus revenue estimates increase by 13%

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

Consensus revenue estimates fall by 18%

First half 2023 earnings released: EPS: €0.021 (vs €0.08 in 1H 2022)

Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates

Innate Pharma S.A. Announces Executive Changes

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Consensus revenue estimates decrease by 40%, EPS upgraded

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Price target increased by 8.3% to €6.37

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

News Flash: Analysts Just Made A Massive Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts

No longer forecast to breakeven

Consensus revenue estimates increase by 340%

Innate Pharma SA Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

Rainbows and Unicorns: Innate Pharma S.A. (EPA:IPH) Analysts Just Became A Lot More Optimistic

Consensus revenue estimates increase by 11%

Innate Pharma S.A. Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Price target decreased to €6.18

Innate Pharma S.A. to Report First Half, 2023 Results on Sep 14, 2023

Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?

Innate Pharma SA Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

Consensus estimates of losses per share improve by 41%

First half 2022 earnings: EPS and revenues exceed analyst expectations

Innate Pharma S.A. (EPA:IPH) Analysts Are Reducing Their Forecasts For This Year

Consensus revenue estimates fall by 11%

Price target decreased to €7.48

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Consensus EPS estimates have been downgraded.

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

Innate Pharma S.A. Announces Supervisory Board Changes

Industry Analysts Just Made A Dazzling Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Consensus forecasts updated

Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts